{{Rsnum
|rsid=1574091
|Gene=FGF12
|Chromosome=3
|position=192364293
|Orientation=plus
|GMAF=0.3884
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FGF12
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 2.7 | 31.0 | 66.4
| HCB | 40.4 | 50.7 | 8.8
| JPT | 39.8 | 48.7 | 11.5
| YRI | 27.2 | 43.5 | 29.3
| ASW | 16.1 | 46.4 | 37.5
| CHB | 40.4 | 50.7 | 8.8
| CHD | 39.4 | 41.3 | 19.3
| GIH | 31.0 | 51.0 | 18.0
| LWK | 20.0 | 57.3 | 22.7
| MEX | 12.3 | 43.9 | 43.9
| MKK | 23.7 | 49.4 | 26.9
| TSI | 1.0 | 28.4 | 70.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1574091
|Name_s=
|Gene_s=FGF12
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109379
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1574091
|overall_frequency_n=44
|overall_frequency_d=128
|overall_frequency=0.34375
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}